D
피씨엘
241820KOSDAQ의료용품 및 기타 의약 관련제품 제조업35.3 / 100
Reference Date: 2026-06-10
Financial Score10.0 / 40
News Sentiment11.3 / 25
Momentum10.0 / 20
Disclosure4.0 / 15
AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
PCl focuses on developing pharmaceuticals, medical devices, and diagnostic technologies such as biochips and ELISA. The company specializes in advanced medical solutions, including hepatitis diagnostics, multiplex testing platforms, and genetic analysis.
Number of Employees
—
Average Salary
—
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 13.514.0Point
PBR
2.36Industry Average 2.142.5Point
Higher than industry avg (caution)
ROE
-236.30Industry Average -3.613.5Point
65.5x industry avg (excellent)
Debt Ratio
203.20Industry Average 50.270.0Point
4.0x industry avg (risky)
Trend 2022~20240.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼81.3% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼81.8% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -146.6% (declining, 2yr)
Detailed News Sentiment
1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 45
- Negative피씨엘, 지난 11일 회생절차 개시신청
피씨엘이 자금난으로 회생절차를 신청함에 따라 주가에 부정적 영향이 예상됩니다.
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 6,040Won52-week high 6,04052-week low 6,040
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
2 totalPositive 0Neutral 0Negative 2
- Negative주요사항보고서(회생절차개시신청)2026-05-12
- Negative기타시장안내 (회생절차 개시신청 관련 시장안내)2026-05-12